SCHEMBL23142003

SCHEMBL23142003

CC(C)n1c(=O)ccc2cnc(S(C)(=O)=O)nc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 6/20 0.53
CCND1 P24385 6/20 0.53
CCND2 P30279 3/20 0.53
CCND3 P30281 3/20 0.53
CDK2 P24941 4/20 0.53
CCNE1 P24864 3/20 0.53
CCNT1 O60563 2/20 0.53
CDK9 P50750 2/20 0.53
CDK6 Q00534 2/20 0.53
AURKA O14965 1/20 0.49
LIMK1 P53667 1/20 0.49
AURKB Q96GD4 1/20 0.49
MAPK8 P45983 13/20 0.48
MAPK10 P53779 11/20 0.48
MAPK9 P45984 8/20 0.48
CCNA2 P20248 2/20 0.45
CCNB2 O95067 1/20 0.45
CCNE2 O96020 1/20 0.45
CDK1 P06493 1/20 0.45
FGFR1 P11362 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29990571 1.00 CDK4 (0.53) CDK4CCND1CCND2CCND3CDK2
SCHEMBL23141845 0.89 CDK4 (0.43) CDK4CCND1CCND2CCND3CDK2
SCHEMBL30719003 0.89 CDK4 (0.43) CDK4CCND1CCND2CCND3CDK2
SCHEMBL23141843 0.89 CDK4 (0.43) CDK4CCND1CCND2CCND3CDK2
SCHEMBL23141955 0.86 CDK4 (0.43) CDK4CCND1CCND2CCND3CDK2
SCHEMBL30718947 0.86 CDK4 (0.43) CDK4CCND1CCND2CCND3CDK2
SCHEMBL23141959 0.86 CDK4 (0.43) CDK4CCND1CCND2CCND3CDK2
SCHEMBL23142044 0.85 CDK4 (0.45) CDK4CCND1CCND2CCND3CDK2
SCHEMBL23141802 0.85 CDK4 (0.45) CDK4CCND1CCND2CCND3CDK2
SCHEMBL23141804 0.85 CDK4 (0.45) CDK4CCND1CCND2CCND3CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12521395-B2 Gem-disubstituted heterocyclic compounds and their use as IDH inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2026-01-13 US disclosed
EP-4055015-B1 GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2025-04-02 EP disclosed
US-12018023-B2 Heterocondensed pyridones compounds and their use as IDH inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2024-06-25 US disclosed
US-12018023-B2 Heterocondensed pyridones compounds and their use as IDH inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2024-06-25 US disclosed
US-12018023-B2 Heterocondensed pyridones compounds and their use as IDH inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2024-06-25 US disclosed
CN-112469719-B Heterocondensed pyridone compounds and their use as IDH inhibitors 内尔维亚诺医疗科学公司 2024-01-23 CN disclosed
US-20230110180-A1 CDK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-13 US disclosed
US-20230000871-A1 GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2023-01-05 US disclosed
US-20230000871-A1 GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2023-01-05 US disclosed
EP-4055015-A1 GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2022-09-14 EP disclosed
CN-115038700-A Gem disubstituted heterocyclic compounds and their use as IDH inhibitors 内尔维亚诺医疗科学公司 2022-09-09 CN disclosed
EP-3797107-B1 HETEROCONDENSED PYRIDONE COMPOUNDS AND THEIR USE AS IDH INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2022-08-10 EP disclosed
US-20210206759-A1 HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2021-07-08 US disclosed
US-20210206759-A1 HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2021-07-08 US disclosed
EP-3797107-A1 HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS Nerviano Medical Sciences S.r.l. (IT) 2021-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018023-B2 Heterocondensed pyridones compounds and their use as IDH inhibitors IDH1, IDH2, IDH3A CDK4 199/4885CCND1 360/4885CCND2 311/4885
US-20210206759-A1 HETEROCONDENSED PYRIDONES COMPOUNDS AND THEIR USE AS IDH INHIBITORS IDH1, IDH2, IDH3A CDK4 199/4885CCND1 360/4885CCND2 311/4885
US-20230000871-A1 GEM-DISUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR USE AS IDH INHIBITORS IDH1, IDH2, IDH3A CDK4 444/4885CCND1 1448/4885CCND2 1009/4885
US-20230110180-A1 CDK2 DEGRADERS AND USES THEREOF CDK2, CDK20, CDK1 CDK4 4/4885CCND1 49/4885CCND2 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.